AstraZeneca has reported positive outcomes from the BaxHTN Phase III trial, indicating that the highly selective aldosterone synthase inhibitor (ASI), baxdrostat, significantly lowered the mean seated ...

AstraZeneca is in advanced talks with Summit Therapeutics over a potential $15 billion deal for the lung cancer drug ivonescimab.

Summit Therapeutics and AstraZeneca are discussing a partnership deal worth as much as $15 billion, Bloomberg News reported on Thursday, citing people familiar with the matter. Under the potential ...

Land of opportunity Since AstraZeneca has quite a presence in the U.S. healthcare market and does much of its business in the country, it makes abundant sense to shift the main stock market ...

AstraZeneca P/E Compared to Competitors The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against ...

Fresh concerns have emerged about the platelet studies underpinning the FDA approval of ticagrelor, AstraZeneca's multibillion-dollar heart drug. A new BMJ investigation reveals data ...

Pressure is piling on London's stock exchange, with reports that British pharma giant AstraZeneca may move its listing to the U.S. delivering yet another blow this week. CEO Pascal Soriot is ...

Losing Astrazeneca would be far more than a headline. It would be a turning point – and not the kind we can easily come back from. The good news is there’s still time to fix this.

AstraZeneca PLC AZN shares rallied 2.79% to £104.02 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX rising 0.28% to 8,785.33 ...

Reports are circulating that AstraZeneca shares could be moving off the London exchange with its CEO favouring a US market listing. The post What will happen to my AstraZeneca shares if it moves its ...